Erice Statement 2009: communication, medicines and patient safety by unknown
Letter to the Editors
Erice Statement 2009: communication, medicines
and patient safety
TwelveyearsaftertheoriginalEriceDeclaration,thiscurrent
statement was also prepared in Erice, by an international
groupofvolunteerprofessionals,representingthemselves,
and drawn from a broad range of stakeholder interests.
TheoriginalEriceDeclarationof1997wasavisionarystate-
ment of the achievable ideals for drug safety communica-
tionatthetime,muchofwhichremainspotentandrelevant
today.Since then,however,the landscape has changed:
Pharmacovigilance now extends to broader concerns
relating to the safety of patients taking medicines,
including medication error, off-label use, counterfeit
products, erosion of trust and the potential risks to
humans from drug residuals in the environment
Dramatic information technology and electronic media
developments worldwide have changed the nature of
communications of all kinds
The expansion and complexity of stakeholder involve-
ment,and particularly societal and patient expectations,
have radically altered the demands on healthcare pro-
viders and drug safety professionals.
New priorities and challenges have emerged as a result of
the changes in these and other areas.Continued progress
towards the ideals expressed in the original Erice Declara-
tion is inﬂuenced—and sometimes hindered—by scien-
tiﬁc and technical, but also political, ﬁnancial, social and
psychological factors.
 The authentic needs and wishes of the multiplicity of
stakeholders,often with diverse and sometimes conﬂict-
ing interests,are not well known.
 Active research must be undertaken to understand
stakeholders’ perceptions, requirements, roles and
interactions
 Reciprocal partnerships must be built and managed
based on mutual respect, sound knowledge, and with
clear and agreed roles and responsibilities
 Targeted messages must be developed at a level of
complexity matched to the abilities and needs of audi-
ences,and using the richness of modern resources.
 There is extensive existing safety knowledge and experi-
enceoutsidethedrugsafetydomain,andwithinit,thatis
not exploited and shared between individuals, disci-
plines and systems concerned with patient safety.
 Medicines safety communications with patients and
the general public must be focused on achieving a
culture of dialogue and joint-responsibility for safe and
rational therapy
 Recognized health authorities must provide guidance
for all audiences on ﬁnding,interpreting and assessing
the reliability of safety information from existing
sources, including unregulated information on the
internet
 Existingknowledgeandexperienceindrugsafetycom-
munication must be given a much higher priority in all
areas of professional education and training.
 Decisions in relation to drug regulation and therapy
involve probabilistic assessments of risks and beneﬁts,
often based on limited information. Fear of litigation
hampers open debate and transparency over judge-
ments behind decisions, and clarity of information can
be compromised by legal and legalistic concerns.
 A positive safety culture must be established,based on
team-working processes and thinking that acknowl-
edge responsibility, are free from blame and allocate
accountability.
 The presence of widely dispersed drugs and drug
metabolites in the environment poses a potential direct,
and indirect,risk to humans.
 The nature and extent of the potential risks must be
further investigated and assessed
 Safe disposal of medicines must be promoted, and
appropriate facilities set up and used
 Further measures may have to be taken to reduce drug
discharge into the environment,including education
 The promotion of rational drug use should reduce
the volume of medicines ﬁnding their way into the
environment.
 Progressintheareaofgatheringandstoringhealthinfor-
mation brings with it challenges in ethics,and in assess-
ing and managing quality, of both the data and the
systems.
 Active efforts must be made to promote and seek
publicapprovaloftheuseofanonymizedpatientinfor-
mation as essential for research and safe and effective
therapy
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highest level of security and quality to achieve public
trust and willingness to contribute anonymized per-
sonal information.
 The media and professional communicators have an
important role, not only as safety partners, but also in
scrutinising the performance of drug safety systems.
 New ways to cooperate with the media as professional
equals must be explored to help in the provision of
balanced,comprehensible,trustworthy and interesting
safety information to the public on a regular basis,
apart from speciﬁc announcements or reports of prob-
lems or crises.
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